MAIA - AMEX

MAIA Biotechnology, Inc.

MAIA·AMEX

$1.49

+4.2%

HealthcareBiotechnology

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$90.59M

EPS-0.7000

P/E Ratio-2.13

Earnings Date08/10/2026

-627.41%

Return on Invested Capital

134%

3Y+239.0%

5Y-182.0%

10Y+26.0%

-942.65%

Return on Equity

47%

3Y+409.0%

5Y-574.0%

10Y-125.0%

-230.78%

Return on Assets

3Y+76.0%

5Y-74.0%

10Y-38.0%

MAIA Biotechnology, Inc. Management Team

MAIA · AMEX

Dr. Sergei M. Gryaznov Ph.D.

Chief Scientific Officer

Compensation

$521,661

Born 1960(Age 66)

Dr. Vlad Vitoc M.B.A., M.D.

Co-Founder, President, Chief Executive Officer & Chairman of the Board of Directors

Compensation

$722,961

Born 1970(Age 56)

Linda Moreira

Company Secretary

Mr. Jeffrey C. Himmelreich

Head of Finance and Principal Financial & Accounting Officer

Compensation

$306,500

Born 1976(Age 50)

male

INSIDER TRANSACTIONS

MAIA Biotechnology, Inc. Insider Positioning

MAIA · AMEX

During the last 12 months, insiders have purchased $279K worth of MAIA shares, with no selling activity reported.

3 Months

Bought

149.7K

203.78K

Sold

0.00

Net Activity

+204K

+$204K

3-6 Months

Bought

57.2K

70.00K

Sold

0.00

Net Activity

+70K

+$70K

6-9 Months

Bought

4.6K

5.49K

Sold

0.00

Net Activity

+5K

+$5K

9-12 Months

Bought

0.00

Sold

0.00

Net Activity

+$0

Top Buyers

Smith Stan

Director

136.8K shares•3 transactions

$176K

Vitoc Vlad

Director, 10 Percent Owner, Officer: Chief Executive Officer

72.7K shares•1 transactions

$101K

Gryaznov Sergei

Officer: Chief Scientific Officer

2.0K shares•1 transactions

$3K

Top Sellers

No selling activity

Insider Activity Analysis

Net Insider Sentiment

Bullish

Strong bullish signal with $279K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.

Buy/Sell Ratio

∞:1

Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.

Recent Trend (3 Months)

$204K

Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.

Insider Participation

High Buying

3 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.

Insider Activity Insight

Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.

SEC PROXY FILINGS

SEC Filings

MAIA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
DEF 14A DEF 14A 2026 N/A	April 07, 2026	May 21, 2026	2026	View Filing
DEF 14A DEF 14A 2025 N/A	April 08, 2025	May 22, 2025	2025	View Filing
DEF 14A DEF 14A 2024 N/A	April 16, 2024	May 24, 2024	2024	View Filing
DEF 14A DEF 14A 2023 N/A	April 19, 2023	May 25, 2023	2023	View Filing

Showing 1 to 4 of 4 filings

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.